BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31453041)

  • 1. Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer.
    Hughes RT; Helis CA; Soike MH; Levine BJ; Farris M; Blackstock AW
    Cureus; 2019 Jun; 11(6):e4969. PubMed ID: 31453041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
    Eze C; Guggenberger JE; Schmidt-Hegemann NS; Kenndoff S; Taugner J; Käsmann L; Schönecker S; Flörsch B; Li M; Belka C; Manapov F
    Cancer; 2022 Jun; 128(12):2358-2366. PubMed ID: 35417563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT.
    Shen J; Yang D; Chen M; Jiang L; Dong X; Li D; Yu R; Yu H; Shi A
    Front Oncol; 2021; 11():644852. PubMed ID: 34221967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of risk factors of radiation-induced toxicity in limited-stage small cell lung cancer treated with hypofractionated intensity-modulated radiotherapy].
    Zhao JJ; Bi N; Zhang T; Wang JY; Deng L; Wang X; Chen DF; Dai JR; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):627-633. PubMed ID: 37462020
    [No Abstract]   [Full Text] [Related]  

  • 5. Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity.
    Rock C; Sood S; Cao Y; Shelton S; Chen RC; Wang F
    Radiat Oncol; 2023 Aug; 18(1):128. PubMed ID: 37533092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.
    Adkison JB; Khuntia D; Bentzen SM; Cannon GM; Tome WA; Jaradat H; Walker W; Traynor AM; Weigel T; Mehta MP
    Technol Cancer Res Treat; 2008 Dec; 7(6):441-7. PubMed ID: 19044323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer.
    Yung T; Giuliani ME; Le LW; Sun A; Cho BC; Bezjak A; Brade A; Hope AJ
    Curr Oncol; 2012 Aug; 19(4):e264-9. PubMed ID: 22876155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
    Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
    Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Aghdam N; Lischalk JW; Marin MP; Hall C; O'Connor T; Campbell L; Suy S; Collins SP; Margolis M; Krochmal R; Anderson E; Collins BT
    Front Oncol; 2021; 11():728519. PubMed ID: 34912703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.
    Yang D; Cui J; Zhao J; You J; Yu R; Yu H; Jiang L; Li D; Xu B; Shi A
    Thorac Cancer; 2020 Mar; 11(3):754-761. PubMed ID: 32012484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
    Iyengar P; Zhang-Velten E; Court L; Westover K; Yan Y; Lin MH; Xiong Z; Patel M; Rivera D; Chang J; Saunders M; Shivnani A; Lee A; Hughes R; Gerber D; Dowell J; Gao A; Heinzerling J; Li Y; Ahn C; Choy H; Timmerman R
    JAMA Oncol; 2021 Oct; 7(10):1497-1505. PubMed ID: 34383006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer.
    Faria SL; Souhami L; Portelance L; Duclos M; Vuong T; Small D; Freeman CR
    Radiat Oncol; 2006 Nov; 1():42. PubMed ID: 17078878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review.
    Li GJ; Tan H; Nusrat H; Chang J; Chen H; Poon I; Shahi J; Tsao M; Ung Y; Cheung P; Louie AV
    Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38621607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience.
    Raman S; Yau V; Pineda S; Le LW; Lau A; Bezjak A; Cho BCJ; Sun A; Hope AJ; Giuliani M
    Clin Lung Cancer; 2018 Sep; 19(5):e803-e810. PubMed ID: 30007498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
    Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
    Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial.
    Giuliani M; Mathew AS; Bahig H; Bratman SV; Filion E; Glick D; Louie AV; Raman S; Swaminath A; Warner A; Yau V; Palma D
    Clin Lung Cancer; 2018 Jul; 19(4):e529-e532. PubMed ID: 29759332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049).
    Zhou R; Qiu B; Xiong M; Liu Y; Peng K; Luo Y; Wang D; Liu F; Chen N; Guo J; Zhang J; Huang X; Rong Y; Liu H
    Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):387-399. PubMed ID: 37100160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
    Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
    Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.